Johnson Matthey, a global leader in science that provides cleaner air, improved health and more efficient use of natural resources, is celebrating its 200th year in existence. To mark JM’s bicentenary, the company is taking a look back at some of its biggest achievements so far within the Pharma industry. JM is well known for being responsible for the first hypodermic injection into a human in 1854, as well as pioneering aseptic surgery and, in 1870, producing the first sterile dressing. JM also played a major role in discovering and developing the platinum-based, anti-cancer drugs, carboplatin in 1975 and cisplatin in 1977, which are today among the world’s most successful cancer drug treatments. More recently, the company acquired the Pharmorphix® solid form business, bringing world-leading solid state capabilities to JM. Over the past 200 years JM has established itself as a world leader within the Pharma industry, and will continue to innovate and solve complex chemistries to enhance people’s quality of life.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
